{"id":"NCT01338818","sponsor":"Novartis Pharmaceuticals","briefTitle":"Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder","officialTitle":"A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2011-04-20","resultsPosted":"2014-05-26","lastUpdate":"2014-11-24"},"enrollment":299,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit/Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Ritalin LA (methylphenidate hydrochloride extended release)","otherNames":["Ritalin LA, methylphenidate hydrochloride extended release, RIT124D"]}],"arms":[{"label":"Ritalin LA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder","primaryOutcome":{"measure":"Number of Participants With Adverse Events, Serious Adverse Events and Deaths.","timeFrame":"Week 40 - Week 66","effectByArm":[{"arm":"Ritalin LA","deltaMin":208,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":48,"countries":["United States","Belgium","Colombia","Denmark","Germany","Sweden"]},"refs":{"pmids":["35201607","25183661"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":298},"commonTop":["Nasopharyngitis","Headache","Decreased appetite","Dry mouth","Nausea"]}}